This Issue of the Bulletin primarily focuses on psychedelic drug development and business stories, with around 4,000 words of coverage and analysis.
Featured content in this Issue:
- GH Research’s Lead 5-MeO-DMT Candidate Faces Development Hiccup, Potential Hold-Up
- Psychae Therapeutics Scores AUD $4.5m to Develop DMT-Based Candidate
- Cybin Closes $30m Offering
- Brain & Behavior Research Foundation Awards Grants to 8 ‘Young Investigators’ Exploring Psychedelics
- atai Buys Out Remainder of DemeRx’s Ibogaine Asset; Announces Novel 5-HT2A Agonist Candidates
- Compass Pathways Commences UK Portion of Phase 3 Trial, Officially Opens Centre for Mental Health Research and Innovation in London
- Awakn Plans to Commence Enrollment for Phase 3 Study of Ketamine for Severe Alcohol Use Disorder in Q1 2024
Elsewhere, we spoke to Booking.com to better understand a headline figure from its travel predictions study, which claims that 14% of travellers are interested in a psychedelic retreat in 2024. We also share clippings and commentary on psychedelics-related news stories from around the world, as well as biotech more broadly.
Companies, organisations and drug candidates mentioned in this Bulletin include: GH Research, GH001, Psychae Therapeutics, Tin Alley Ventures, Reconnect Labs, Filament Health, Psychae Institute, Cybin, Tryp Therapeutics, PharmaDrug, atai Life Sciences, DemeRx, DMX-1002, EntheogeniX, EGX-A, EGX-B, Cyclica, EMP-01, VLS-01, Compass Pathways, COMP369, NHS, Awakn Life Sciences, AWKN-P001, Sunstone Therapies, Kanna Health, Relmada Therapeutics, Nue Life, Beckley Waves, Enthea.
This content is for Pα+ Subscribers
This is the first issue of our Psychedelic Bulletin that’s exclusively for Pα+ subscribers. Head to our Join page to learn more, or sign in to your account.
